Mounjaro is a branded tirzepatide formulation. Tirzepatide is a dual GIP and GLP-1 receptor agonist, studied for its role in activating both GIP and GLP-1 receptor signaling and the downstream glucose-regulation and appetite-related pathways associated with these receptors.

This branded formulation is used in controlled laboratory workflows and in-vitro systems examining GIP and GLP-1 receptor activity, glucose-regulation mechanisms, and appetite-related hormone signaling. It is applied in structured research models characterizing receptor activity and downstream pathway interactions.

Mounjaro supports analytical studies and cell-based models involving dual GIP/GLP-1 receptor agonism, insulin- and glucose-related pathways, satiety signaling, and broader metabolic efficiency. It is relevant for pathway characterization and assay development focused on endocrine and metabolic cross-talk within controlled study frameworks.

Mounjaro is suited for researchers and investigators who require a branded, standardized tirzepatide reference when studying dual-incretin receptor signaling, glucose regulation, and metabolic mechanisms within controlled study frameworks.